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ABSTRACT Immunotherapy represents an attractive option for the treatment of
chronic hepatitis B virus (HBV) infection. The HBV proteins polymerase (Pol) and HBx
are of special interest for antigen-specific immunotherapy because they are essential
for viral replication and have been associated with viral control (Pol) or are still ex-
pressed upon viral DNA integration (HBx). Here, we scored all currently described
HBx- and Pol-derived epitope sequences for viral indispensability and conservation
across all HBV genotypes. This yielded 7 HBx-derived and 26 Pol-derived reported
epitopes with functional association and high conservation. We subsequently pre-
dicted novel HLA-binding peptides for 6 HLA supertypes prevalent in HBV-infected
patients. Potential epitopes expected to be the least prone to immune escape were
subjected to a state-of-the-art in vitro assay to validate their HLA-binding capacity.
Using this method, a total of 13 HLA binders derived from HBx and 33 binders from
Pol were identified across HLA types. Subsequently, we demonstrated interferon
gamma (IFN-) production in response to 5 of the novel HBx-derived binders and 17
of the novel Pol-derived binders. In addition, we validated several infrequently de-
scribed epitopes. Collectively, these results specify a set of highly potent T cell
epitopes that represent a valuable resource for future HBV immunotherapy design.
IMPORTANCE Multiple HBV-derived T cell epitopes have been reported, which can
be useful in a therapeutic vaccination strategy. However, these epitopes are largely
restricted to HLA-A*02, which is not dominantly expressed in populations with high
HBV prevalence. Thus, current epitopes are falling short in the development of a
global immunotherapeutic approach. Therefore, we aimed to identify novel epitopes
for 6 HLA supertypes most prevalent in the infected population. Moreover, estab-
lished epitopes might not all be equally effective as they can be subject to different
levels of immune escape. It is therefore important to identify targets that are crucial
in viral replication and conserved in the majority of the infected population. Here,
we applied a stringent selection procedure to compose a combined overview of ex-
isting and novel HBV-derived T cell epitopes most promising for viral eradication.
This set of T cell epitopes now lays the basis for the development of globally effec-
tive HBV antigen-specific immunotherapies.
KEYWORDS hepatitis B virus, HBx, polymerase, cytotoxic T cells, epitope selection,
epitope discovery, immunotherapy
Chronic hepatitis B virus (CHB) infection affects roughly 250 million people world-wide (1) and is a main cause of cirrhosis and hepatocellular carcinoma (HCC).
Chronically infected patients can be treated with expensive viral replication inhibitors,
but complete viral eradication as in hepatitis C virus infection is rare. In fact, curative
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treatment remains highly demanded since CHB infection is expected to remain a global
health problem for many years (2).
Immunotherapy had already emerged in the 1990s as a promising option to treat
CHB. T cell responses are considered essential for viral clearance but are scarce or
exhausted in CHB patients (3–7). Still, they can be boosted or induced via several
therapeutic strategies, e.g., vaccination or adoptive transfer of engineered hepatitis B
virus (HBV)-specific T cells (8–22). However, these strategies are hampered by the lack
of an HLA-broad epitope repertoire against which antiviral T cells can be directed. The
majority of currently described epitopes are restricted to HLA-A*02, which is highly
prevalent in Caucasians (23, 24). Yet HLA-A*02 is expressed in only roughly 40% of the
world’s population and is not dominant in Asian and African populations (23), whereas
especially these populations show a high HBV prevalence (2). Thus, it is vital to identify
non-HLA-A*02-restricted epitopes, especially for HLA types prevalent among Asians
and Africans, such as HLA-A*24 or HLA-B*07.
Next to a lack of HLA diversity, the current HBV-derived epitope repertoire is skewed
by the fact that many reports focus on dissecting T cell responses against the HBV
surface antigen (HBsAg) or core antigen (HBcAg). However, the proteins X (HBx) and
polymerase (Pol) also pose interesting targets, as both are vital for viral persistence
(25–27) and interfere with the antiviral immunity of the host (28). Furthermore, HBx is
expressed only in infected hepatocytes and is involved in the development of HCC (29).
The expression of HBx is likely to be retained upon HCC formation because of the
productive integration of the HBx gene into the host genome (30–32). Collectively, this
provides a rationale to target HBx in patients suffering from CHB as well as HBV-related
HCC (33, 34). Besides HBx, Pol represents an interesting immunotherapeutic target. Pol
is more immunogenic than HBsAg in HBV transgenic mice (35), and high frequencies of
Pol-specific T cells are associated with viral control after discontinuation of viral
replication inhibitors in patients (36). This implies that Pol-specific T cells retain their
function throughout the course of chronicity and can contribute to immune control in
vivo. Others have explored strategies to predict HLA-I epitopes from Pol but focused
exclusively on a single HLA type or assessed only a limited number of HBV sequences
(37–40). Taken together, the identification of novel, non-HLA-A*02-restricted HLA-I
epitopes derived from HBx and Pol would greatly benefit generic anti-HBV immuno-
therapy design.
In addition to a limited epitope repertoire, there is another hurdle in the develop-
ment of HBV-directed immunotherapy. Established epitopes might not all be equally
effective, as they can be subjected to different levels of viral mutagenesis and subse-
quent immune escape. Indeed, previous reports clearly demonstrate that HBV is subject
to immune pressure and that mutation of epitope sequences leads to immune evasion
(41–43) or even HBV reactivation (44, 45). Importantly, in the case of immune escape,
responsive memory T cells may still linger in patients despite the loss of epitope
presentation on target cells. Thus, prevalent detection of cognate T cells by itself offers
no guarantee of clinical relevance. Long-term efficacy of generic immunotherapy can
be expected to be dictated by epitope preservation across the patient population, in
which infection is caused by different HBV genotypes. Moreover, amino acids con-
served between genotypes are more likely to have functional importance to the virus.
After all, mutation of functional sequences would lead to a loss of viral fitness, which
drives subsequent negative selection. Indeed, amino acids essential for HBV replication
are almost exclusively highly conserved (46–48). Taken together, T cell responses
directed against conserved epitopes from functional protein domains would benefit
the majority of patients while simultaneously hampering viral replication and immune
escape.
Here, we have taken an effort to tackle the above-mentioned issues by integrating
viral indispensability, genomic variation, HLA binding, and immunogenicity to identify
the best HBx- and Pol-derived T cell epitopes for immunotherapy across 6 of the most
prevalent HLA supertypes within the HBV-infected population. The results of this study
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pave the way for the development of globally effective HBV antigen-specific immuno-
therapies.
RESULTS
Ranking of the most optimal reported HBx- and polymerase-derived epitopes.
We first set out to rank reported epitopes for HBx and Pol based on protein conser-
vation and function using a comprehensive database called Hepitopes (24, 49). From
Hepitopes, we extracted all unique epitopes identified in human hosts for HBx (n 14)
and Pol (n 50) (Fig. 1, left), which were found to be largely HLA-A*02 restricted (see
Fig. S1 in the supplemental material). To rank these epitopes based on conservation, all
protein sequences for HBx and Pol were extracted from a large public HBV repository
(HBVdb) (50, 51) (Fig. 1, right) and used to compute an overall consensus sequence
across viral genotypes (see Materials and Methods). Based on this sequence, a conser-
vation score (prevalence) was calculated (Fig. 2 and 3 for HBx and Pol, respectively). To
additionally rank functional associations, we extended our analysis to described func-
tional domains and amino acids that severely impaired viral function upon mutation
(see Tables S1 and S2 in the supplemental material for details on reviews and studies
used) (26, 46–48, 52–69). These were additionally aligned to the consensus sequences
of HBx and Pol (Fig. 2 and 3, respectively, arrows and bottom panels). As expected,
functional domains and essential amino acids mostly aligned to highly conserved
regions. Finally, we used the acquired information on conservation and functionality to
rank all reported HBx- and Pol-derived epitopes (Tables 1 and 2, respectively).
We argued that epitopes in which the least conserved amino acid was still present
in 80% of all sequences tested would be targetable in the majority of the population.
Combining this criterion with the preference for functional association, we found 7
HBx-derived and 26 Pol-derived sequences reported as epitopes across HLA types to be
preferential targets for global immunotherapy (italic type in Tables 1 and 2, respec-
tively). If documented, Tables 1 and 2 additionally show response percentages and
frequencies in acute/resolved HBV infection and HBV-related HCC for all HBx- and
Pol-derived epitopes reported in Hepitopes. Patients suffering from acute infection can
clear the disease spontaneously, implying that HBV-specific T cells frequently identified
in acute patients or resolved individuals may have contributed to viral clearance. Thus,
such responses may be of particular interest to boost or induce in chronic patients. For
peptides extracted from Hepitopes that evoke a response in at least 25% of patients
(Tables 1 and 2, boldface type), we identified 4 Pol-derived sequences against which
responses were significantly more prevalent in patients with acute or resolved infection
(Table 2, asterisks).
Prediction of novel HLA-I-binding peptides derived from HBx and polymerase.
To extend epitope coverage within the infected population, we set out to identify novel
peptides that can bind at least 1 out of 6 HLA supertypes prevalent in Caucasian,
African, or Asian populations for which in vitro assays to confirm binding were also at
our disposal (i.e., supertypes HLA-A*01, -A*02, -A*03, -A*24, -B*07, and -B*08). We first
predicted binders spanning 8 to 14 amino acids for supertype-representative HLA types
using the established in silico prediction tool NetMHCpan to make a frequency distri-
bution of predicted binders (Fig. 2 and 3, gray bar diagrams). The densities of all
predicted binders per amino acid were similar between Pol and HBx (means standard
deviations [SD] of 16.36 12.62 for Pol and 15.60 9.49 for HBx; P 0.57 by a
Mann-Whitney test). Predicted binders spanning 9 to 11 amino acids were subse-
quently aligned to our maps outlining conservation and function (Fig. 2 and Fig. S2)
since 9- to 11-mers are most likely to represent an epitope (70). Individual peptide
positions for Pol are exclusively shown in Fig. S2 to enable high-resolution zoom-in on
peptides of interest, which would not be possible in Fig. 3.
The prediction yielded totals of 251 potential novel HLA binders for HBx and 1,655
for Pol (Fig. 1, right), including both weak and strong binders (i.e., predicted Net-
MHCpan rank scores based on past performance [Fig. S3]). Of these, we selected the
most promising peptides for validation of HLA binding in an in vitro UV-based assay
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(71). For practical and economic reasons, we aimed to test the binding of 96 unique
peptide sequences over both proteins and across HLA types. We included 2 well-
described HLA-A*02 epitopes from HBcAg and Pol (c18-27 and p549-557, respectively)
to put the binding capacity of our newly identified binders into context. For other HLA
types, we also aimed to include a known HBV epitope for comparison, but only less
established epitopes reported once or twice were available (see Fig. 5, solid underlin-
ing). This also included c123-130 since this was the only HBV-derived epitope registered
Ranking of described epitopes
table 1 + 2
ranking
compute
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 selection
(fig 2, 3, 4)
Hepitope db HBVdb
Discovery of novel epitopes
functional domains
&
loss of function mutations
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FIG 1 Workflow of epitope ranking and discovery. All amino acid sequences from HBx and Pol were
extracted from the publicly available database HBVdb and used to compute a consensus sequence
and conservation score (top right) (see Materials and Methods). The resulting consensus sequences
were subsequently used in NetMHCpan to predict sequences of HLA-binding peptides across the 6
most common HLA supertypes in the HBV-infected population. This yielded 251 and 1,655 HBx- and
Pol-derived potential HLA binders, respectively. A total of 113 of these were selected for in vitro
validation based on predicted HLA binding, conservation, and reported functional association within
the viral protein. This yielded 13 HBx-derived and 33 Pol-derived validated HLA binders. All of these
were subsequently tested for immunogenicity, in which 6 HBx- and 24 Pol-derived peptides elicited
IFN- responses in an ELISA. In addition, all currently known Pol- and HBx-derived epitopes were
extracted from the publicly available database Hepitopes (top left) and ranked according to
conservation score and reported functional association. These findings are summarized in Table 4
(bottom center).
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FIG 2 Alignment of reported and predicted CD8 T cell targets based on protein conservation and function for
HBx. The centered bar diagram depicts the length of the consensus sequence of the HBx protein (see Materials
and Methods), in which the conservation score across viral genotypes is indicated by a color code (key) for each
amino acid. Reported epitopes obtained from the Hepitopes database are aligned to this sequence and shown
on top. Below this, potential novel binders predicted by NetMHCpan (9 to 11 amino acids) are depicted for each
HLA supertype representative. The gray histogram represents the frequency of each amino acid within all
predicted binders (8 to 14 amino acids long) over the protein sequence. Essential amino acids for which mutation
leads to a loss of viral persistence are indicated by arrows matching the color of the conservation score.
Functional domains are depicted at the bottom according to the nomenclature of HBVdb. References describing
the experimental evidence for essential amino acids and functional domains are listed in Table S1 in the
supplemental material.
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in Hepitopes for HLA-B*08. Potential binders were prioritized based on peptide length
(9-mers preferred), predicted HLA-binding strength, conservation, and functional im-
portance of included amino acids (Fig. 4). For HLA-A*01 and HLA-A*24, there was an
unsatisfactory number of predicted binders for HBx to maintain our strict thresholds for
conservation and peptide length. For these conditions, we therefore also included
some less conserved peptides or peptides spanning 8 to 12 amino acids (Fig. 5, stars,
and Table S3). Furthermore, we selected several additional peptides that were infre-
quently (once or twice) reported as an epitope in the literature and therefore consid-
ered unestablished (Fig. 5, solid underlining). Moreover, peptides that were predicted
Terminal Protein
RNA binding RNA binding
T3
RNA           packaging
Spacer Reverse Transcriptase RNAse H
120 240 360 480 600 720 8431
Polymerase
YMDD
< 80 80-90
90-95 95-100
100
Legend conservation (%)
FIG 3 Alignment of reported and predicted CD8 T cell targets based on protein conservation and function for
polymerase. The gray histogram represents the frequency distribution of predicted binders (8 to 14 amino acids
long) over the protein sequence. The conservation score (key) of each amino acid is shown as a horizontal
color-coded bar diagram. Essential amino acids for which a single or combined mutation leads to a loss of viral
persistence (50%) are indicated by arrows matching the color of the conservation score for that particular amino
acid. Amino acids that are predicted to be vital for three-dimensional (3D) conformation are indicated with stars.
General domains are depicted according to previously determined nomenclature (48), in which the T3 domain and
the YMDD motif are also represented. References describing the experimental evidence for essential amino acids
and functional domains are listed in Table S2 in the supplemental material. A high-resolution figure depicting
described epitopes and potential novel binders (9 to 11 amino acids) is available in Fig. S2 in the supplemental
material to allow zoom-in on single peptides and regions of interest.
TABLE 1 Ranking of reported epitopes for HBx based on conservation and functiona
Amino acid
positions
Amino acid
sequence HLA type Cons (%)
No. of papers
reporting epitope
Presence of
functional amino
acid/domain
% responders (no. of responders/
total no. of subjects tested)
Acute Chronic HCC
133–141 VLGGCRHKL A*02:01 98.1 2 Yes/yes 0 (0/20) 0 (0/10)
52–60 HLSLRGLPV A*02:01 98.0 3 Yes/yes 0 (0/20) 19 (3/16)
135–143 GGCRHKLVC A*11:01 97.7 1 Yes/yes
92–100 VLHKRTLGL A*02:01 89.8 5 Yes/yes 0 (0/20) 19 (3/16)
91–100 KVLHKRTLGL A*02:01 89.8 1 Yes/yes
99–108 GLSAMSTTDL A*02 80.7 2 No/yes
102–110 AMSTTDLEA A*02:01 80.7 1 No/yes
15–23 VLCLRPVGA A*02:01 88.4 1 No/no
8–16 QLDPARDVL A*02:01 80.2 4 No/no 25 (1/4) 0 (0/20) 0 (0/10)
115–123 CLFKDWEEL A*02:01 39.9 1 Yes/yes 50 (3/6)
84–92 NAHQVLPKV A*02:01 39.9 1 Yes/no
97–105 TLGLAAMST A*02:01 3.1 1 Yes/yes
140–148 KLVCSPAPC A*02:01 63.4 1 No/yes 50 (3/6)
44–53 VVPTDHGAHL A*02:01 11.3 1 No/no
aEpitopes are classified into different categories (gray/white areas) by ranking first on conservation [Cons (%)] and subsequently on functionality (Presence of
functional amino acid/domain). Epitopes in italic type are preferred immunogenic targets because of their high conservation across HBV genotypes (conservation of
80%) and previous association with functional importance (Presence of functional amino acid/domain). The epitope in boldface type evokes a response in at least
25% of patients within a patient group, which was not significantly more prevalent than in other patient groups.
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to bind several HLA types were prioritized throughout the selection procedure, which
led to a total set of 113 potential peptide-HLA combinations to test in an in vitro
binding assay: 45 for HBx and 68 for Pol. The majority of the peptides mapped to highly
conserved areas with established functional importance. The median conservation
scores among selected peptides were above 93% for HBx and even above 96% for Pol
(Fig. S4).
TABLE 2 Ranking of reported epitopes for polymerase based on conservation and functiona
Amino acid
positions
Amino acid
sequence HLA type(s)
Cons
(%)
No. of papers
reporting
epitope
Presence of
functional amino
acid/domain
% responders (no. of
responders/total no. of subjects
tested)
Acute Chronic HCC
389–397 VVDFSQFSR A*33, A*11, A*68:01 99.8 3 Yes/yes
388–397 LVVDFSQFSR A*11, A*33:01, A*68:01 99.8 1 Yes/yes 5 (1/22)
746–755 GTDNSVVLSR A*11 99.4 1 Yes/no
374–383 FLVDKNPHNT A*02:03 99.3 1 Yes/yes
55–63 KVGNFTGLY A*03, A*11 99.2 1 Yes/yes 9 (2/22)
368–378 RVTGGVFLVDK A*11 99.1 1 Yes/yes
369–378 VTGGVFLVDK A*03, A*11 99.1 1 Yes/yes
166–173 ASFCGSPY A*01:01, A*29:02, A*30:02 97.3 1 Yes/yes
166–175 ASFCGSPYSW B*58:01 97.3 1 Yes/yes
756–764 KYTSFPWLL A*24:02 96.8 2 Yes/no 93 (13/14)* 48 (10/21)
147–156 YLHTLWKAGI A*02 96.7 2 Yes/yes 0 (0/10)
149–159 HTLWKAGILYK A*03, A*11, A*31:01, A*33:01, A*68:01 96.7 1 Yes/yes 5 (1/22)
150–158 TLWKAGILY A*03, A*11 96.7 1 Yes/yes
150–159 TLWKAGILYK A*03, A*11 96.7 1 Yes/yes 18 (5/28)
653–661 ALMPLYACI A*02:01, A*02:02, A*02:03, A*02:04, A*02:06 96.4 4 Yes/no 20 (4/20) 0 (0/9) 0 (0/10)
651–659 YPALMPLYA B*07:02, B*35:01, B*51, B*54:01 96.4 1 Yes/no 0 (0/12)
365–374 TPARVTGGVF B*35, B*51 95.5 1 Yes/yes 17 (2/12)
549–557 YMDDVVLGA A*02:01 92.5 4 Yes/no 15 (2/13) 0 (0/21) 0 (0/10)
549–558 YMDDVVLGAK A*03 92.5 1 Yes/no
789–797 DPSRGRLGL B*07:02 91.0 1 Yes/no
500–508 KLHLYSHPI A*02:03 99.5 3 No/yes 0 (0/10)
440–448 HPAAMPHLL B*07:02 99.5 1 No/yes 0 (0/12)
47–55 NVSIPWTHK A*03, A*11, A*68:01 98.3 1 No/yes 5 (1/21)
418–426 LLSSNLSWL A*02:01 95.4 1 No/yes
422–430 NLSWLSLDV A*02 95.4 1 No/yes 0 (0/10)
502–510 HLYSHPIIL A*02 89.2 2 No/yes
770–778 WILRGTSFV A*02 99.6 2 No/no
771–780 ILRGTSFVYV A*02:01 99.6 2 No/no 43 (3/7) 0 (0/9)
531–539 SAICSVVRR A*11, A*33:01, A*68:01 98.8 1 No/no 9 (2/22)
573–581 FLLSLGIHL A*02:01, A*02:06 96.2 18 No/no 59 (50/85)* 13 (9/70) 0 (0/10)
665–674 QAFTFSPTYK A*03, A*11, A*68:01 95.9 2 No/no 14 (3/21)
524–533 FLLAQFTSAI A*02:01 94.4 2 No/no 0 (0/10)
525–533 LLAQFTSAI A*02 94.4 1 No/no 0 (0/10)
541–550 FPHCLAFSYM B*07:02, B*35:01, B*51, B*53:01, B*54:01 92.5 1 No/no 0 (0/12)
623–631 PVNRPIDWK A*03, A*11 91.1 1 No/no
763–771 LLGCAANWI A*02:01 85.0 1 No/no
61–69 GLYSSTVPV A*02:01 57.7 1 Yes/yes 8 (1/12)
485–493 NLYVSLLLL A*02:01 52.3 1 Yes/yes
744–752 IIGTDNSVV A*02:01 17.1 1 Yes/no
361–369 RIPRTPSRV A*02 4.1 1 Yes/yes
338–346 CLSLIVNLL A*02 3.9 1 Yes/yes
651–659 YPALMPLSA B*54:01 0.0 1 Yes/no
453–461 GLSRYVARL A*02:01, A*02:02, A*02:03 68.3 12 No/yes 50 (39/78)* 6 (5/87) 0 (0/10)
453–461 GLPRYVARL A*02:01, A*02:07 30.8 1 No/yes
466–474 RIINNQHRT A*02:01 24.3 1 No/yes
261–269 GSGPTHNCA A*11:01 43.7 1 No/no
814–822 SLYADSPSV A*02:01 43.3 5 No/no 25 (11/44)* 0 (0/22)
671–679 PTYKAFLSK A*11:01 31.4 1 No/no
796–804 GLSRPLLRL A*02 21.3 1 No/no
573–581 FLLSLGIHI A*02 0.2 1 No/no
aEpitopes are classified into different categories (gray/white areas) by ranking first on conservation [Cons (%)] and subsequently on functionality (Presence of
functional amino acid/domain). Epitopes in italic type are preferred immunogenic targets because of their high conservation across HBV genotypes (conservation of
80%) and previous association with functional importance (Presence of functional amino acid/domain). Epitopes in boldface type evoke a response in at least 25%
of patients within a patient group, which was significantly more prevalent than in the other patient groups in 4 cases (asterisks).
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Excluded: sequence in
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rank score
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3
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9
7
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7
9
9
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A*02 A*03
most promising
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remaining peptides to
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HLA-type
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A*01
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epitopes for validation
HBx
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10
FIG 4 Selection of peptide candidates to test in an in vitro HLA binding assay. Selection was based on conservation,
functionality, peptide length, and rank score. Either the default rank score of 2.0 or an adjusted value for the
appropriate HLA type was used based on past performance of the in vitro binding assay (see Fig. S3 in the
supplemental material), as indicated in the sequential diagram steps. Peptides that were predicted to bind several
HLA supertype representatives were prioritized throughout the selection procedure in case the number of peptide
(Continued on next page)
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In vitro binding capacity of preselected peptides derived from HBx and poly-
merase. Next, the HLA-binding capacity of selected peptides was tested in a UV-based
in vitro binding assay. Peptides were classified as HLA binders when their binding
capacity was higher than 25% of that of a known high-affinity peptide (Table S4).
HLA-A*11:01 and HLA-A*03:01 were both tested as members of the HLA-A*03 super-
type since many HBV-infected patients are Asian and HLA-A*11:01 is more prevalent in
this population than the supertype representative HLA-A*03:01, which is more preva-
lent in Caucasians (72). We identified 13 binders for HBx and 33 for Pol across HLA
supertypes, including novel binders that have been described previously in the context
of another HLA type (Fig. 5A to G, dotted underlining, and Fig. 5H). Notably, both HBx-
and Pol-derived binders were identified for each HLA supertype tested. For HLA-A*02,
the well-established epitopes c18-27 and p549-557 scored even better than the posi-
tive control (Fig. 5B). In contrast, binding of infrequently reported epitopes (Fig. 5, solid
underlining) could not always be verified.
Immunogenicity of selected HLA-binding peptides. Finally, the immunogenicity
of all HBx- and Pol-derived binders was assessed to determine which binders would be
most interesting for the development of an antigen-based HBV-targeting immunother-
apy. Peripheral blood mononuclear cells (PBMCs) from blood donors who had previ-
ously resolved an HBV infection were expanded in the presence of peptide pools,
followed by single-peptide restimulation and an interferon gamma (IFN-) enzyme-
linked immunosorbent assay (ELISA). As expected, IFN- production was detected in
response to the well-established epitopes c18-27 and p549-557 (Fig. 6B). Furthermore,
IFN- production was highly variable, and some donors generally seemed to respond
better than others (Fig. 6). In total, we observed responses against 5 completely novel
HBx- and 17 novel Pol-derived peptides. Additionally, we observed IFN- production in
response to 1 HBx- and 3 Pol-derived less established epitopes, although none of these
responses were very high (Fig. 6, solid underlining). Importantly, 4 additional Pol-
derived peptides elicited responses in donors negative for the HLA type in which these
peptides previously yielded epitopes (Fig. 6, dotted underlining, and Table 3). Finally,
there was no measurable response to 6 Pol-derived and 7 HBx-derived HLA binders in
any of the donors tested (Fig. 6, gray boxes). Table 4 shows our main findings, in which
all prioritized HBx- and Pol-derived epitopes from Tables 1 and 2 are categorized
according to the HLA (super)types of interest with reference to all HLA types for which
they were described. Only epitope p166-175 was prioritized in our analysis but was not
described for any of the HLA (super)types of interest. Table 4 also includes all peptides
against which IFN- responses were detected.
DISCUSSION
The aim of this study was to rationally address two major hurdles in developing a
generic antigen-based immunotherapy for HBV: (i) the lack of prioritization of epitopes
in further studies toward clinical implementation and (ii) the shortage of non-HLA*02-
restricted epitopes.
To address the first issue, we ranked all currently described HBx- and Pol-derived
epitopes according to conservation and association with viral indispensability. Conser-
vation patterns were similar to those previously reported, with the most conspicuous
observation being that the spacer domain of Pol is extremely variable (27, 42, 73). We
obtained all reported HBx- and Pol-derived epitopes used for this study from the
Hepitopes database, which also contains less firmly established epitopes. Thus, our
ranking might contain epitopes that need further validation prior to implementation in
immunotherapies.
Four Pol-derived epitopes were more frequently described in acute or resolved
FIG 4 Legend (Continued)
candidates exceeded 8 for each HLA type. After each step, we excluded epitopes that we considered established
(reported in a minimum of 2 papers) using the Hepitopes database. Gray numbers in the central peptide table
represent the conditions for which inclusion was not further pursued.
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p108-116
p149-158
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C D
FIG 5 Binding capacities of all preselected peptide candidates. Binding of predicted peptide candidates is represented as
percent binding of positive-control peptides (Pos. Ct.), which have a high affinity for the indicated HLA type. Means and
standard deviations are depicted for controls (black), binders (25% of the positive control) (gray), and nonbinders (25%
of the positive control) (white). As a negative control (Neg. Ct.), we included a known nonbinding peptide for each HLA type
and a condition under which no peptide was present. Solid underlined peptides are infrequently described as epitopes for
the HLA type tested. Dotted underlined peptides have so far been described only as an epitope for another HLA type, of
which cross-reactive binders are summarized in the table. Stars indicate the peptides that did not meet our length and
conservation thresholds.
de Beijer et al. Journal of Virology
April 2020 Volume 94 Issue 7 e01663-19 jvi.asm.org 10
 o
n
 M
arch 31, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
infection than in chronic infection. Of these, p756-764 and p573-581 scored the highest
in conservation. p756-764 contains at least 1 amino acid important for viral persistence,
but no functional relevance has been described for p573-581. Since the DNA sequence
coding for p573-581 completely overlaps that of HBsAg, we interrogated the literature
for the functional relevance of amino acids in this overlapping part of HBsAg. However,
c123-130 Peptide Sequence
p166-175 
p365-374 
A*24:02
B*07:02
p500-508 
Reported for
Newly identified cross-reactive peptides 
Novel binder for
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FIG 5 (Continued)
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no functional association was reported (73–75). Although T cell responses to HBsAg are
frequently deleted/exhausted and potentially difficult to revive because of antigen
overstimulation (76–78), this does not necessarily translate to Pol since HBsAg and Pol
are not produced at equal levels. Besides, HBsAg and Pol are derived from different
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FIG 6 Immunogenicity of HLA-binding peptides. DMSO-subtracted IFN- concentrations produced by expanded PBMCs from 9 HBV resolvers were
measured in response to all HLA binders identified, including the well-established c18-27 and p549-557 epitopes (B). Gray boxes present the number
of responsive donors as a fraction of the total number of subjects tested for each peptide. Solid underlined HLA binders are infrequently described as
epitopes for the HLA supertype tested. Dotted underlined HLA binders have so far been described only as an epitope for another HLA supertype. Stars
indicate the peptides that did not meet our length and/or conservation thresholds.
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open reading frames (ORFs), which results in a different amino acid sequence for HBsAg
than for Pol despite being based on largely the same DNA sequence (79). Thus,
although not yet linked to function, the high conservation score still nominates
p573-581 for utilization in generic immunotherapy. In contrast, the other two epitopes
that were highly prevalent in acute patients, p453-461 and p814-822, were much less
conserved (68.3% and 43.3%, respectively) and did not contain any amino acids with
demonstrated functional relevance. These epitopes might therefore be less interesting
for the development of global immunotherapy.
Although we rationalized to prioritize conserved peptide sequences, we reckon that
regions containing prevalent sequence variation could still be interesting if immuno-
genicity is preserved. Novel T cell responses may arise due to cross-reaction between
the variant and the original sequence (80, 81). This could, e.g., be true for p453-461, of
which 2 sequence variants are described as epitopes in the same HLA context.
However, whether a variation can induce cross-reactive T cells needs to be experimen-
tally assessed for each peptide sequence and its variant individually, which is beyond
the scope of our study.
The second issue in developing generic antigen-specific immunotherapy for HBV is
that non-HLA-A*02-restricted epitopes are vital but scarce. Here, we identified novel
epitopes for 6 HLA supertypes most prevalent in the HBV-infected population. Super-
types HLA-A*02, HLA-A*03, and HLA-B*07 altogether cover 85% of the Caucasian,
African, and Asian populations (23). HLA-A*24 further extends coverage to the Asian
population, whereas HLA-A*01 and HLA-B*08 extend to the Caucasian population. For
all these HLA supertypes combined, the predicted binder quantity was clearly higher
for Pol than for HBx. This was mostly because HBx is smaller (154 amino acids) than Pol
(843 amino acids) since we found similar densities of predicted binders for both
proteins. Opposed to this observation, Pol, out of all HBV-derived proteins, previously
showed the highest density of predicted CD8 epitopes, while HBx seemed more
subject to immune-pressure-induced deletion of epitopes (82). However, that study
included only 107 HBV-derived sequences of a single genotype, whereas our study
includes more than 7,000 sequences for each protein with all genotypes represented.
TABLE 3 HLA-I types of HBV resolver donors used for immunogenicity testing of HLA
binders
Donor HLA-A type HLA-B type HLA-C type
1 03:01 07:02 07:02
02:01 07:02 07:02
2a 01 08 06
11 13 07
3 02:01 18:01 12:03
25:01 07:02 07:02
5 01:01 08:01 07:01
24:02 07:02 07:02
6 01:01 08:01 07:01
02:01 40:01 03:04
7 03:01 52:01 02:02
11:01 51:01 12:02
8 23:01 49:01 07:01
11:01 18:01 12:02
9a 24 15 01
31 22 14
10 01:01 07:02 07:01
02:01 44:02 07:02
aThe HLA type is available in 2-digit resolution only.
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TABLE 4 Recommendation of the most potent T cell epitopes classified by HLA (super)type
HLA typeb
Reported epitope Novel/validated epitopea
Designation Sequence HLA (super)type(s) Designation Sequence HLA (super)type
A*01 p166-173 ASFCGSPY A*01:01, A*29:02, A*30:02 p549-557 YMDDVVLGA A*01:01
A*02 p147-156 YLHTLWKAGI A*02 p368-376 RVTGGVFLV A*02:01
p374-383 FLVDKNPHNT A*02:03 p407-415 FAVPNLQSL A*02:01
p418-426 LLSSNLSWL A*02:01 p693-701 GLCQVFADA A*02:01
p422-430 NLSWLSLDV A*02 x15-23 VLCLRPVGA A*02:01
p500-508 KLHLYSHPI A*02:03
p502-510 HLYSHPIIL A*02
p549-557 YMDDVVLGA A*02:01
p653-661 ALMPLYACI A*02:01, A*02:02, A*02:03, A*02:04, A*02:06
x52-60 HLSLRGLPV A*02:01
x91-100 KVLHKRTLGL A*02:01
x92-100 VLHKRTLGL A*02:01
x99-108 GLSAMSTTDL A*02
x102-110 AMSTTDLEA A*02:01
x133-141 VLGGCRHKL A*02:01
A*03 p47-55 NVSIPWTHK A*03, A*11, A*68:01 p275-283 CLHQSAVRK A*03:01
p55-63 KVGNFTGLY A*03, A*11 p55-63 KVGNFTGLY A*03:01
p149-159 HTLWKAGILYK A*03, A*11, A*31:01, A*33:01, A*68:01 x70-78 ALRFTSARR A*03:01
p150-158 TLWKAGILY A*03, A*11
p150-159 TLWKAGILYK A*03, A*11
p369-378 VTGGVFLVDK A*03, A*11
p388-397 LVVDFSQFSR A*11, A*33:01, A*68:01
p389-397 VVDFSQFSR A*33, A*11, A*68:01
p549-558 YMDDVVLGAK A*03
A*11 p47-55 NVSIPWTHK A*03, A*11, A*68:01 p164-173 RSASFCGSPY A*11:01
p55-63 KVGNFTGLY A*03, A*11 p369-378 VTGGVFLVDK A*11:01
p149-159 HTLWKAGILYK A*03, A*11, A*31:01, A*33:01, A*68:01 x104-113 STTDLEAYFK A*11:01
p150-158 TLWKAGILY A*03, A*11
p150-159 TLWKAGILYK A*03, A*11
p368-378 RVTGGVFLVDK A*11
p369-378 VTGGVFLVDK A*03, A*11
p388-397 LVVDFSQFSR A*11, A*33:01, A*68:01
p389-397 VVDFSQFSR A*33, A*11, A*68:01
p746-755 GTDNSVVLSR A*11
x135-143 GGCRHKLVC A*11:01
A*24 p756-764 KYTSFPWLL A*24:02 p166-175 ASFCGSPYSW A*24:02
p167-175 SFCGSPYSW A*24:02
p403-412 SWPKFAVPNL A*24:02
p649-658 CGYPALMPLY A*24:02
p650-658 GYPALMPLY A*24:02
p697-706 VFADATPTGW A*24:02
p755-764 RKYTSFPWLL A*24:02
p756-764 KYTSFPWLL A*24:02
p756-765 KYTSFPWLLG A*24:02
x62-73 AFSSAGPCALRF A*24:02
x110-120 AYFKDCVFKDW A*24:02
B*07 p365-374 TPARVTGGVF B*35, B*51 p365-373 TPARVTGGV B*07:02
p440-448 HPAAMPHLL B*07:02 p365-374 TPARVTGGVF B*07:02
p651-659 YPALMPLYA B*07:02, B*35:01, B*51, B*54:01 p404-412 WPKFAVPNL B*07:02
p789-797 DPSRGRLGL B*07:02 p515-523 IPMGVGLSP B*07:02
p723-731 LPIHTAELL B*07:02
x58-66 LPVCAFSSA B*07:02
B*08 p500-508 KLHLYSHPI B*08:01
p509-517 ILGFRKIPM B*08:01
B*58 p166-175 ASFCGSPYSW B*58:01
aValidated for the tested HLA type (underlining)/tested for an HLA type other than the one previously reported (italics).
bBoldface HLA type indicates groups of epitopes with preference for this particular HLA type in the corresponding gray/white area.
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In the present study, prediction was performed using an established, well-
performing in silico tool. However, it cannot be excluded that potent epitopes remain
unidentified by using this approach. Due to limited resources, we could include only
the most potent peptide candidates, leaving many unexplored. In addition, we have
not further studied functionality in overlapping ORFs with respect to Pol and HBx that
may yield even more epitopes with a low chance of immune escape. However,
unexplored epitopes may still be identified, e.g., by using mass spectrometry on
HLA-eluted peptides (83). We additionally demonstrate that prediction yields many
false-positive HLA binders, highlighting the necessity of validation assays. To investi-
gate which HLA binders would be relevant for future studies, immunogenicity was
assessed in subjects who resolved HBV infection. We performed antigen-specific ex-
pansion to allow detection of responses that might be low if HBV was cleared a long
time ago. Previous reports showed that functional HBcAg-specific CD8 T cells were
significantly less abundant in patients who cleared HBV infection long ago than in
patients who cleared infection more recently (84, 85). Indeed, some donors generally
gave a stronger IFN- response than others, which might reflect more recent clearance.
Thus, high-level IFN- production in our experiments might not directly translate to
strong immunogenicity. Inversely, epitopes yielding low IFN- responses should not be
immediately disregarded as promising.
Recent reports showed that Pol cognate T cells might be more exhausted in terms
of phenotype and function than HBcAg-directed T cells (39, 40, 86). Nonetheless, as also
noted by Bertoletti and Kennedy (87), this does not dismiss Pol as a suitable target for
immunotherapy. First of all, Pol-derived epitopes have a role in viral control after
discontinuation of antiviral therapy (36). Second, data were based on HBeAg-negative
patients in whom HBeAg-mediated exhaustion of HBcAg T cells due to overlapping
sequences between HBeAg and HBcAg may have been (partially) reverted (88). The fact
that HBcAg immunity may be of relatively good quality in HBeAg-negative patients,
however, renders HBcAg an interesting target for immunotherapy, especially in this
patient group. Finally, the above-mentioned papers primarily focused on only 1 or 2
epitopes. Thus, the conclusion that Pol-directed T cells in general are more exhausted
than HBcAg cognate T cells should be taken with prudence and needs further inves-
tigation for more epitopes across different HLA types. The epitopes put forward in our
study would make good tools for such efforts.
We identified a few novel epitopes for which the sequence overlaps that of an
epitope that has previously been described for the HLA type tested. This is most
apparent for the novel epitopes p755-764 and p365-373, of which p755-764 resulted in
superior IFN- production compared to the known epitope p756-764 in both donors
tested. It would now be interesting to investigate how responses to these epitope
variants relate in CHB patients, especially since p755-764 has been the only HBV-derived
epitope described for supertype HLA-A*24 until very recently. For HLA-A*24:02, we studied
the binding capacity of 3 peptides that were recently assessed for the first time in another
study (89). Those authors did not detect cytotoxic T cells against p146-154 and p387-395,
which fits our finding that neither peptide bound HLA-A*24:02. Conversely, we observed
a response to p650-658 in 1 of the 2 HLA-A*24:02-positive donors, whereas none of the
3 HBV resolvers described by Yamamiya et al. responded. This difference may be due
to the low number of resolvers tested and emphasizes the need to validate the novel
epitopes described here in more subjects prior to implementation in immunotherapies.
In addition, further characterization of cognate T cell populations in different patient
populations ex vivo is desired to determine which epitope has true clinical potential.
Because we identified epitopes for 6 HLA supertypes that have limited overlap, this
would require vast numbers of difficult-to-obtain samples, which is beyond the scope
of this paper. Our immunogenicity assays aimed to explore which novel HLA binders
had the intrinsic potential to boost immune responses, and we have delivered 30
epitopes that now provide a rational starting point for more elaborate efforts.
Although this study focused on CD8 T cell epitopes, we recognize the importance
of CD4 T cell and B cell responses in viral clearance. Importantly, for studies pursuing
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HLA-II targets, the maps generated here detailing where HBx and Pol are most
conserved and vulnerable to immune attack are also highly relevant. As such, they
might aid in the design of synthetic long peptide (SLP) vaccines. SLPs can be designed
to harbor both HLA-I and HLA-II epitopes and are processed more efficiently by
dendritic cells than whole proteins (90). Importantly, SLPs directed against human
papillomavirus (HPV)-induced neoplasms and malignancies have already been proven
successful in clinical trials (91), and we have previously reported that SLPs show
promise for use in HBV patients (92). The present study especially facilitates SLP design
through the identification of immunogenic sequences that were previously described
as epitopes in the context of a different HLA type than the ones tested here. For
example, p365-374 was previously reported for HLA-B*35 and HLA-B*51 but now gave
a response in 4/4 donors positive for HLA-B*07. The phenomenon that one peptide
sequence can yield an epitope in several HLA supertypes has been described for other
viral sequences (93) and opens up the interesting possibility of targeting a broad
proportion of the infected population with just a single amino acid sequence. Because
of this high population coverage, sequences yielding epitopes in multiple HLA types
may be particularly interesting targets to include in different forms of immunotherapy
such as SLP vaccination. In addition, our comprehensive analysis of HBx and Pol also
aids in the development of T cell therapies by allowing selection of T cell receptors
(TCRs).
In conclusion, we provide a rational methodology for the selection and discovery of
the most potent HBV-derived HLA-I T cell epitopes. In addition, we propose novel T cell
epitopes for a broad range of HLA (super)types covering the vast majority of the
HBV-infected population that target the virus where it is most vulnerable. Collectively,
the results of this study provide a valuable resource to guide future development of
HBV-specific immunotherapies.
MATERIALS AND METHODS
Peptide prediction and selection. A frequency table was downloaded from HBVdb V42.0 (50, 51)
based on HBV sequences of all genotypes for HBx (n 8,127) and Pol (n 7,489). Positions where a gap
(indicated by “”) was most frequent were deleted, after which the dominating amino acid at each
position was determined. Percentages of sequences containing the dominant amino acid were calcu-
lated as the conservation score. Combining all dominant amino acids for Pol led to the consensus
sequence MPLSYQHFRKLLLLDDEAGPLEEELPRLADEGLNRRVAEDLNLGNLNVSIPWTHKVGNFTGLYSSTVPVFN
PEWQTPSFPDIHLQEDIINRCQQFVGPLTVNEKRRLKLIMPARFYPNVTKYLPLDKGIKPYYPEHVVNHYFQTRHYLHTL
WKAGILYKRETTRSASFCGSPYSWEQELQHGRLVFQTSKRHGDESFCSQSSGILSRSPVGPCIQSQLKQSRLGLQPQQG
SLARRQQGRSGSIRARVHPTTRRSFGVEPSGSGHIDNSASSSSSCLHQSAVRKAAYSHLSTSKRQSSSGHAVELHNIPPS
SARSQSEGPVFSCWWLQFRNSKPCSDYCLSHIVNLLEDWGPCTEHGEHHIRIPRTPARVTGGVFLVDKNPHNTTESRLV
VDFSQFSRGNTRVSWPKFAVPNLQSLTNLLSSNLSWLSLDVSAAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSNSRII
NNQHGTMQNLHDSCSRNLYVSLLLLYKTFGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLAFS
YMDDVVLGAKSVQHLESLYTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYVIGSWGTLPQEHIVQKIKQCFRKLPVNR
PIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYACIQAKQAFTFSPTYKAFLCKQYLNLYPVARQRPGLCQVFADATPT
GWGLAIGHQRMRGTFVAPLPIHTAELLAACFARSRSGAKLIGTDNSVVLSRKYTSFPWLLGCAANWILRGTSFVYVPSA
LNPADDPSRGRLGLYRPLLRLPFRPTTGRTSLYAVSPSVPSHLPDRVHFASPLHVAWRPP.
The resulting consensus sequence for HBx was determined to be MAARLCCQLDPARDVLCLRPVGAE
SRGRPLSGPLGTLPSPSPSAVPADHGAHLSLRGLPVCAFSSAGPCALRFTSARRMETTVNAHQVLPKVLHKRTLGLSA
MSTTDLEAYFKDCVFKDWEELGEEIRLKVFVLGGCRHKLVCSPAPCNFFTSA.
These sequences were loaded into NetMHCpan3.0 (94) to predict binders for HLA supertype
representatives HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-B*07:02, and HLA-B*08:01.
Furthermore, the cumulative frequency of each amino acid in any predicted HLA binder was calculated.
Predicted HLA binder densities were compared between Pol and HBx using a two-tailed Mann-Whitney
test. Amino acid sequences of reported functional domains were aligned with the consensus sequence
using the NCBI tool COBALT (95). Similarly, amino acids that alone or in combination were previously
associated with a loss of viral replication were aligned to the consensus sequence. Functionally
associated amino acids were more numerous for Pol than for HBx. Therefore, an additional threshold of
a 50% loss of viral persistence for Pol was introduced to select the most crucial amino acids. Tables S1
and S2 in the supplemental material present literature references on functional domains and amino
acids. The most promising predicted binders were selected for each protein and HLA type separately.
Binding of the selected peptides was subsequently validated in an in vitro binding assay as described
below.
In vitro HLA binding validation. Synthetic peptides (Peptide 2.0 Inc.) of selected potential HLA
binders were used in an in vitro binding assay as described previously (96). In brief, peptide exchange
reactions were performed by exposure for 30 min of conditional peptide-HLA complexes (pHLA)
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(0.53 M) to long-wavelength UV using a 366-nm UV lamp (Camag) in the presence or absence of the
indicated peptide (50 M). Subsequently, the peptide exchange efficiency was analyzed using an HLA-I
enzyme-linked immunosorbent assay (ELISA), which detects beta-2-microglobulin of peptide-stabilized
HLA-I complexes in an exchange reaction mixture. To this end, streptavidin (2 g/ml) was bound to
polystyrene microtiter wells (Nunc MaxiSorp). After washing and blocking, the HLA complex present in
exchange reaction mixtures or controls was captured by the streptavidin on the microtiter plate via its
biotinylated heavy chain (incubation for 1 h at 37°C). Nonbound material was removed by washing.
Subsequently, horseradish peroxidase (HRP)-conjugated antibody to human beta-2-microglobulin
(0.6 g/ml; Sanquin Reagents BV) was added (incubation for 1 h at 37°C). After the removal of the
nonbound HRP conjugate by washing, an ABTS [2,2=-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)di-
ammonium salt] (Sanquin Reagents BV) substrate solution was added to the wells. The reaction was
stopped after 8 min (incubation at room temperature) by the addition of a 2% (wt/vol) oxalic acid
dihydrate stop solution (Sanquin Reagents BV) and read in a Thermo Electron Multiskan Ascent ELISA
reader at 414 nm. Every peptide was independently exchanged twice. Every exchange mixture was
measured in duplicate by the HLA-I ELISA. The absorbances of all the peptides were normalized to the
absorbance of a known HLA allele-specific ligand with high affinity for each corresponding allele
(representing 100%) (Table S4). Negative controls included an HLA allele-specific nonbinder (Table S4)
and UV irradiation of the conditional HLA-I complex in the absence of a rescue peptide.
Determining immunogenicity. Peptides with 25% binding in the in vitro HLA binding assay were
assessed for immunogenicity. Briefly, PBMCs were isolated by Ficoll (GE Healthcare) density centrifuga-
tion from buffy coats of 9 donors who had previously resolved HBV infection. Buffy coats were provided
by the local blood bank with corresponding 2-digit HLA types. Four-digit HLA typing was performed for
7 out of 9 donors using the global screening array (GSA) (Illumina through the Human Genomics Facility,
Erasmus MC Rotterdam) (Table 3). All donors gave written informed consent. PBMCs were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) (Lonza) containing 2% human serum (Sanquin) and
50 IU/ml human interleukin-2 (hIL-2) (Miltenyi) in the presence of peptide pools of a maximum of 5
peptides of interest based on HLA matching at 10 g/ml/peptide. After 14 days, 200,000 cells were
restimulated with the peptides of interest for 48 h at 37°C with 10 g/ml/peptide in triplicate. Superna-
tants from restimulations were subsequently used in a human IFN- (hIFN-) ELISA (BioLegend) accord-
ing to the manufacturer’s instructions. Plates were read at a 450-nm wavelength using an Infinite 200Pro
ELISA reader. hIFN- levels were calculated from background-subtracted optical density (OD) values
(means from triplicates) using a supernatant derived from a previously successful restimulation with
c18-27 that was quantified in a separate ELISA using the hIFN- standard provided by the manufacturer.
HLA binders with a mean OD value of at least the mean plus 2 times the standard deviation (SD) of the
dimethyl sulfoxide (DMSO) control were quantified. HLA binders that did not meet this criterion were
included as nonresponsive (0 pg/ml IFN- produced). HLA binders against which IFN- production was
detected in at least one donor tested were classified as epitopes.
Comparison of response frequencies of described epitopes in acute versus chronic patients.
The Hepitopes initiative previously performed an extensive literature search of the Medline and Embase
databases to collect all HBV-derived HLA-I epitopes from 112 papers (24, 49). All HBx- and Pol-derived
epitopes reported in the Hepitopes database that were identified in human hosts were subjected to NCBI
protein BLAST analysis to verify amino acid positions in the consensus sequence. Presented conservation
scores apply to the least conserved amino acid within an epitope. Epitopes that harbor a minimum of
one amino acid essential for viral replication or that completely span a functional domain are scored with
“yes” for “amino acid” or “domain,” respectively. Epitopes are classified into different categories (gray/
white areas) by ranking first on conservation and subsequently on functionality. Epitopes with equal
scores for both parameters are ranked on the number of papers in which they were mentioned and
subsequently on the number of HLA types for which they were identified. All corresponding papers and
their supplemental material as listed in the Hepitopes database were checked to acquire the cumulative
number of chronic, acute/resolved, and HBV-positive HCC patients responding to each epitope (42,
55–85). A responsive patient was defined as an individual with either positive multimer staining, IFN-
production in an enzyme-linked immunosorbent spot (ELISPOT) assay, or a combination of these
readouts. When peptide pools were used and no responses were found, all peptides tested in that pool
were considered to have given a negative result and were included as such. When peptide pools were
used and responses were found while it was unclear which epitope caused the response, all peptides
tested in that pool were excluded from the analysis for that particular reference. For epitopes evoking
a response in at least 25% of patients in a particular patient group, responses were compared between
patient groups using a two-tailed Fisher exact test followed by the Holms multiple-testing correction (97)
and found significant when the P value was 0.05. For the few epitopes with a response in at least 25%
of HCC patients, patient groups could not be compared due to the lack of data for CHB and acute
hepatitis patients.
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